| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-02-05 | Affiris (Austria) | nomination |
Neurodegenerative diseases | Nomination | ||
| 2015-02-05 | Orion Pharma Animal Health - a part of Orion Corporation (Denmark) Vetoquinol (France) | Orion Pharma Animal Health Sedatives product family alpha 2 -agonists and antagonist Dexdomitor®, Domitor® and Domosedan® and Antisedan® | distribution |
Veterinary medicine | Distribution agreement | |
| 2015-02-04 | Rigontec (Germany) | chief executive officer | nomination | Cancer - Oncology - Infectious diseases | Nomination | |
| 2015-02-03 | Epizyme (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-02-03 | Ayoxxa (Germany) Singapore Eye Research Institute (Singapore) | multiplexing technology platform for protein biomarker detection, ophthalmic diagnostic tools | collaboration |
Ophtalmological diseases - Diagnostic | Collaboration agreement | |
| 2015-02-03 | Theradiag (France) UCB (Belgium) | services |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Services contract | ||
| 2015-02-03 | Moderna Therapeutics (USA - MA) Institut Pasteur (France) | viral diseases and bacterial diseases | R&D |
Infectious diseases | R&D agreement | |
| 2015-02-02 | TxCell (France) Ferring International Center (Switzerland) Trizell Holding (Switzerland) | OvaSave® (antigen-specific type 1 regulatory T (Ag-Treg) cell based immunotherapy) | inflammatory bowel diseases, including Crohn's disease and ulcerative colitis | development |
Autoimmune diseases - Inflammatory diseases - Digestive diseases | Termination of an agreement |
| 2015-02-02 | Nicox (France) InSite Vision (USA - CA) | AzaSite® (1% azithromycin), BromSite™ (0.075% bromfenac), AzaSite Xtra™ (2% azithromycin) | bacterial conjunctivitis, treatment of inflammation and prevention of pain after cataract surgery | licensing development manufacturing production commercialisation |
Ophtalmological diseases | Licensing agreement |
| 2015-02-02 | Merck Serono, a Merck KGaA company (Germany) Takeda Pharmaceutical (Japan) | diabetes and thyroid brands including Glucophage® (metformin hydrochloride), and Glucophage XR®, Glucovance® (metformin and glibenclamide), Euthyrox® (levothyroxine sodium), Jodid® (potassium iodide; Iodbalance™ in Russia), and Thyrozol® (thiamazole) | commercialisation licensing |
Metabolic diseases - Endocrine diseases - Hormonal diseases - Cardiovascular diseases | Commercialisation agreement | |
| 2015-02-02 | Symbiosis Pharmaceutical Services (UK) | nomination |
Technology - Services | Nomination | ||
| 2015-02-02 | Mylan (USA - PA) Theravance (USA - CA) | TD-4208 (biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester) | chronic obstructive pulmonary disease (COPD) and other respiratory diseases | development commercialisation |
Inflammatory diseases - Respiratory diseases | Development agreement |
| 2015-01-30 | CMC Biologics (Denmark - USA) Serendex Pharmaceuticals (Denmark) | Factor VIIa for pulmonary administration | diffuse alveolar hemorrhage | licensing development |
Cardiovascular diseases - Lung diseases - Hematological diseases | Licensing agreement |
| 2015-01-29 | Merck KGaA, Merck Serono (Germany) Symphogen (Denmark) | Sym004 | advanced metastatic colorectal cancer, squamous cell carcinoma of the head and neck | licensing |
Cancer - Oncology | Termination of an agreement |
| 2015-01-29 | Symphogen (Denmark) | clinical development unit in New Jersey | opening of new premises | Cancer - Oncology | Opening of new premises | |
| 2015-01-29 | Epizyme (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-01-29 | Valneva (France) Immune Targeting Systems (UK) | Hepatitis B vaccine candidates in combination with adjuvant IC31® | hepatitis B | development licensing commercialisation |
Infectious diseases | Licensing agreement |
| 2015-01-29 | Icon (Ireland) | new global innovation hub | creation of a new centre |
Technology - Services | Construction of new premises | |
| 2015-01-29 | OSE Pharma (France) Simbec-Orion (UK) | Tedopi® | HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients who have failed on previous therapy | clinical research |
Cancer - Oncology - Rare diseases | Clinical research agreement |
| 2015-01-29 | Amgen (USA - CA) The Familial Hypercholesterolemia Foundation (USA - CA) Stanford Medicine (USA - CA) | FIND (FLAG, IDENTIFY, NETWORK, DELIVER) FH initiative | familial hypercholesterolemia | collaboration |
Cardiovascular diseases - Genetic diseases - Rare diseases | Collaboration agreement |
